Stocks in play: Abattis Bioceuticals Corp.

Announced the appointments of Kent McParland, Brazos Minshew, Shawn Balaghi and Jim Carter to the Company’s leadership team and Wolfgang Richter to its Board of Directors. Kent McParland has been appointed as Chief Financial Officer and Chief Operating Officer, replacing David Whitney as Chief Financial Officer, and Rene David as Chief Operating Officer. Mr. McParland, a chartered professional accountant, joins Abattis following fifteen years in public practice with Grant Thornton, MNP and Deloitte. He has experience working in multiple industries and expertise in project management and change management. Dr. Brazos Minshew has been appointed as Head of the Company’s Medical Advisory Board and as President of the Corporate Advisory Board of Vergence Naturals Ltd., a wholly-owned subsidiary of Abattis. In such roles, Mr. Minshew is expected to drive the sales and development of new formulations and to launch new brands and product offerings for the Company.Jim Carter has been appointed as the Head of Mergers and Acquisitions Advisory and will drive the Company’s upcoming expansion activities and mergers and acquisitions strategy. Mr. Carter will also act as an advisor to the Board of Directors on financial matters. Shawn Balaghi has been appointed as the Company’s Head of Corporate Development. Mr. Balaghi has over 20 years’ experience working with public markets and draws on a strong understanding of the cannabis space, having worked with numerous licensed producers under the Access to Cannabis for Medical Purposes Regulations (ACMPR). Wolfgang Richter has been appointed as a director of the Company, bringing the number of directors of the Company to six. Mr. Richter draws on relevant experience with the cannabis industry, having previously served as a director of Northern Vine Canada Inc., a former subsidiary of the Company. Abattis Bioceuticals Corp. shares ATT:CNX are trading off 2.33 percent at $0.21.